Beaumont Financial Advisors Reduces Stake in Johnson & Johnson

Firm sells nearly 7,000 shares of pharmaceutical giant in Q4 2025

Apr. 5, 2026 at 7:55am

Got story updates? Submit your updates here. ›

Beaumont Financial Advisors LLC, a prominent investment management firm, decreased its position in Johnson & Johnson (NYSE: JNJ) by 5.6% in the fourth quarter of 2025, according to a recent SEC filing. The firm sold 6,993 shares, leaving it with a total of 118,215 shares of the pharmaceutical company's stock, which makes up 1.6% of Beaumont's overall portfolio.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a strong presence in pharmaceuticals, medical devices, and consumer products. Changes in institutional ownership of JNJ shares can provide insights into broader market sentiment and investment trends within the healthcare sector.

The details

According to the 13F filing, Beaumont Financial Advisors sold the 6,993 shares of Johnson & Johnson during the fourth quarter of 2025. The firm's total position in JNJ is now valued at $24.47 million, down from $25.95 million at the end of the previous quarter. This reduction in Beaumont's JNJ holdings comes as the stock has seen strong performance, with shares rising over 15% in the past year.

  • Beaumont Financial Advisors filed its Q4 2025 13F report on April 5, 2026.
  • The firm sold 6,993 shares of Johnson & Johnson during the fourth quarter of 2025.

The players

Beaumont Financial Advisors LLC

A prominent investment management firm that decreased its position in Johnson & Johnson by 5.6% in Q4 2025.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company that is one of the world's largest healthcare conglomerates.

Got photos? Submit your photos here. ›

The takeaway

This reduction in Beaumont Financial Advisors' Johnson & Johnson holdings, while relatively small, could signal a broader shift in investor sentiment around large-cap pharmaceutical stocks as the market navigates economic uncertainty. However, JNJ remains a core holding for many institutional investors given the company's diversified business model and strong track record of growth.